Table 3.
Organism | Carbapenemase | MLST | Year of Isolation | Clinical History Location | Other Properties | Reference |
---|---|---|---|---|---|---|
A. baumannii | OXA-51-like | 2009/2010 | NA | MDR, outbreak | [2] | |
E. coli | NDM-5 | ST540 | 2013 | Bangladesh | NDM-5 in Japan | [4] |
K. pneumoniae | NDM-1 | ST76 | 2014 | Indonesia | NDM-1 in Japan | [4] |
K. pneumoniae | KPC-2 | ST11 | 2016 | Indonesia | PDR | [5,32] |
P. aeruginosa | IMP-7 | ST357 | 2016 | Indonesia | XDR | [5] |
A. baumannii | OXA-23, OXA-66 | ST1050 | 2016 | Indonesia | XDR | [5] |
E. coli | OXA-48-like | 2018 | India | MDR | [6] | |
K. pneumoniae | VIM-1 | ST70 | 2018 | Greece | VIM-1 in Japan | This study |
K. oxytoca | IMP-1 | ST88 | 2018 | NA | Epidemic in Japan | This study |
E. cloacae | IMP-1 | ST252 | 2018 | NA | Epidemic in Japan | This study |
E. cloacae | IMP-10 | ST78 | 2018 | NA | IMP-10 in Japan | This study |
NA, not available; MDR, multidrug-resistant; PDR, pandrug-resistant; XDR, extensively drug-resistant.